Is MPT a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Medical Properties Trust (MPT) rests on Tenant re-tenanting and rent recovery: MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and has guided toward more than $1 billion in annualized cash rent by year-end 2026. The bear case rests on mPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Analysts covering it publish targets from $4.25 to $7.00 against a $3.01 price, so even the professionals disagree by 54% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Medical Properties Trust, Inc. trades on the New York Stock Exchange under the ticker MPT and is one of the largest owners of hospital real estate in the world. Its model is sale-leaseback: it buys hospital buildings from operators, then leases the property back under long-term net leases where the tenant covers taxes, insurance, and maintenance. The portfolio spans general acute care hospitals, behavioral health facilities, and post-acute sites across the United States and Europe, and revenue comes almost entirely from contractual rent plus interest on loans MPT has made to some of its tenants. The investment picture is defined by a collapse from its former blue-chip status. After the 2024 bankruptcy of its largest tenant, Steward Health Care, MPT cut its dividend sharply, sold assets, and re-tenanted properties. The slide continued in 2026: as of October 16 the stock closed near $3.09, down about 39 percent year to date and about 41 percent over one year, for a market cap near $1.85 billion. Q1 2026 showed a net profit helped by one-time items, but Q2 2026 slipped back to a small net loss of about $2.6 million on roughly $259 million of revenue. In September MPT closed the sale of two Idaho hospitals to Intermountain Health affiliates for $371 million in cash to MPT and said most of it would go to debt reduction, against roughly $9.7 billion of total debt. It is a turnaround-and-deleveraging story, not a stable income staple, and the next report is due October 29, 2026.
The bull case: what would have to be true for $7.00
The most optimistic published target on MPT is $7.00, +132.6% from the $3.01 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Tenant re-tenanting and rent recovery
MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and has guided toward more than $1 billion in annualized cash rent by year-end 2026. The thesis rests on those replacement tenants actually paying contractual rent on schedule, which would restore cash flow and support the dividend. Quarterly revenue has held in a $237-270 million band over the last four quarters, and analysts expect about $263 million for Q3 2026, so any slippage in cash collection directly hits funds from operations.
2. Deleveraging and refinancing runway
With roughly $9.7 billion of debt and maturities stacked through 2026 and 2027, MPT has been raising secured financing and selling assets to push out its maturity wall. The September 2026 sale of Idaho Falls Community Hospital and Mountain View Hospital brought in $371 million of cash to MPT at a 6.9 percent cap rate, about $130 million above gross book value, and management said a majority would repay debt. Each sale like this shrinks the debt load but also removes rent, so the trade-off between deleveraging and lost income is the single biggest lever on the equity value.
3. Deep-value and high-yield setup
At about $3.09 the $0.36 annual dividend works out to a yield near 11.6 percent, and the stock trades at roughly 0.41 times book value, well below larger healthcare REITs. Several market commentators flagged MPT in October 2026 among high-yield stocks where the price may be signalling a dividend cut, and GAAP earnings do not cover the payout. For investors who believe the tenant base stabilizes, that gap is the potential re-rating; for the market, it is a warning. It is also one of the most heavily shorted REITs, so any confirmation of stability can move the price sharply.
4. European and behavioral health diversification
MPT holds meaningful hospital assets in the United Kingdom, Germany, and other European markets, which diversifies away from any single United States operator or reimbursement regime. A one-time United Kingdom deferred tax benefit boosted Q1 2026 results, and the behavioral health and international portfolios provide rent streams that are somewhat decoupled from the troubled United States acute care tenants.
The bear case: what would have to be true for $4.25
The most pessimistic published target is $4.25, +41.2% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Medical Properties Trust is worth if the risks below bite instead of the drivers above.
MPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Tenant concentration is a recurring problem: the 2024 Steward bankruptcy forced a dividend cut and asset sales, and in March 2026 MPT declared defaults on properties leased to Healthcare Systems of America, its third-largest tenant at about 8 percent of assets, sending the stock down about 8 percent in a day. That March 2026 disclosure triggered securities-fraud investigations by several plaintiff law firms, and MPT has faced securities litigation before tied to its 2019 to 2023 disclosures, so legal and disclosure risk is an ongoing overhang. The dividend is a live question: trailing net income is about -$32 million, the reported payout ratio is far above 100 percent, and a yield above 11 percent shows the market pricing in a possible cut. Asset sales reduce debt but also shrink rent, and BofA Securities trimmed its price target to $4.25 from $5 in August 2026. Hospital operators face reimbursement pressure, staffing shortages, and impairments. Walnut is not an investment adviser, and these factors make MPT materially more speculative than a typical healthcare REIT.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MPT already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MPT
6 analysts cover MPT, with an average target of $5.12 (+70.1% against $3.01) and a split of 3 buy, 3 hold, 2 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MPT forecast and price target page.
How is MPT valued? (as of October 2026)
Snapshot for MPT as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.1 billion (+1.9% YoY latest qtr)
- Net income (TTM): ~-$32 million
- Market cap: ~$1.85 billion
- Stock price: ~$3.09 (YTD -39%)
- Dividend yield: ~11.6% (~$0.36/yr)
- Price to book: ~0.41x
- Total debt: ~$9.7 billion
MPT trades at about 0.41 times book value and 1.7 times sales, a steep discount to larger healthcare REITs like Welltower and Ventas, which reflects its leverage and tenant risk rather than a bargain hiding in plain sight. Q2 2026 brought about $259 million of revenue and a small net loss, after a Q1 profit that leaned on one-time tax and cash-rent items, and the $371 million Idaho hospital sale gives it cash to pay down debt at the cost of future rent. With a yield near 11.6 percent and Q3 results due October 29, the valuation is a classic high-yield, high-risk setup where the discount and the danger are two sides of the same coin.
How do you decide if MPT is a buy?
Rather than asking whether MPT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MPT indirectly through an index or sector ETF before adding more.
What would change your mind on MPT
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Tenant re-tenanting and rent recovery stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: mPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027 fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MPT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MPT against your real portfolio and see your actual exposure before deciding.
Investing in Medical Properties Trust with AI
Connect the broker you already use and ask Walnut's AI how MPT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MPT a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Tenant re-tenanting and rent recovery, with revenue (ttm) at ~$1.1 billion (+1.9% YoY latest qtr). The bear case rests on mPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Analysts covering it are spread from $4.25 to $7.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MPT?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. MPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $4.25, +41.2% from the $3.01 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MPT?
+
Tenant re-tenanting and rent recovery. MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and has guided toward more than $1 billion in annualized cash rent by year-end 2026. The most optimistic analyst target on MPT is $7.00, +132.6% from the $3.01 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MPT?
+
MPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Tenant concentration is a recurring problem: the 2024 Steward bankruptcy forced a dividend cut and asset sales, and in March 2026 MPT declared defaults on properties leased to Healthcare Systems of America, its third-largest tenant at about 8 percent of assets, sending the stock down about 8 percent in a day. That March 2026 disclosure triggered securities-fraud investigations by several plaintiff law firms, and MPT has faced securities litigation before tied to its 2019 to 2023 disclosures, so legal and disclosure risk is an ongoing overhang. The dividend is a live question: trailing net income is about -$32 million, the reported payout ratio is far above 100 percent, and a yield above 11 percent shows the market pricing in a possible cut. Asset sales reduce debt but also shrink rent, and BofA Securities trimmed its price target to $4.25 from $5 in August 2026. Hospital operators face reimbursement pressure, staffing shortages, and impairments. Walnut is not an investment adviser, and these factors make MPT materially more speculative than a typical healthcare REIT. The most pessimistic published target is $4.25, +41.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Medical Properties Trust do?
+
Medical Properties Trust, Inc. is a self-advised real estate investment trust to acquire and develop net-leased hospital facilities.
What would have to change for MPT to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Tenant re-tenanting and rent recovery) stalling in the reported numbers rather than in the narrative, the risk above (mPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Medical Properties Trust do?
+
MPT is a real estate investment trust that owns hospital buildings and leases them back to healthcare operators under long-term net leases. It is one of the largest hospital landlords globally, with acute care, behavioral health, and specialty facilities across the United States and Europe. Its income is almost entirely contractual rent plus interest on tenant loans.
Why has MPT stock fallen so much?
+
The stock collapsed from the mid-teens after its largest tenant, Steward Health Care, went bankrupt in 2024, forcing a sharp dividend cut, asset sales, and re-tenanting. Heavy debt, roughly $9.7 billion, and repeated tenant troubles, including the March 2026 defaults at Healthcare Systems of America, kept pressure on the shares, which closed near $3.09 on October 16, 2026. It is one of the most heavily shorted REITs.
Is MPT facing a securities-fraud lawsuit?
+
MPT faced securities litigation tied to its 2019 to 2023 disclosures, and after a March 2026 statement about defaults by tenant Healthcare Systems of America, several plaintiff law firms announced new securities-fraud investigations. These are ongoing legal overhangs that investors weigh, though the tenant and leverage stresses driving them are ordinary business risks for a hospital REIT under strain.
Walnut is informational, not investment advice, and gives no verdict on MPT. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.